Biopharmaceutical companies in France are utilizing disposable systems to remain competitive by shortening the downtime required between different product batches. This shift represents a fundamental realignment of industrial priorities, moving away from the rigid, permanent infrastructure of the
A record 383 vials of LYMPHIR were ordered in July, establishing a new performance benchmark for the company’s expanded 29-member nationwide sales infrastructure. This milestone represents a significant pivot for Citius Pharmaceuticals as it transitions from a clinical-stage entity into a
Evidence suggests that neuroinflammation in CAR T-cell patients can persist as a localized metabolic crisis even after systemic inflammatory markers in the bloodstream have been successfully reduced. This finding highlights the complex nature of Chimeric Antigen Receptor (CAR) T-cell therapy, a
Identifying CD31 protein expression in engineered tissue constructs serves as a vital indicator that a functional internal blood vessel network has begun to take shape. For patients grappling with catastrophic bone injuries or the aftermath of tumor removals, the quest for a permanent solution
The persistent search for a definitive treatment for Duchenne muscular dystrophy (DMD) has entered a sophisticated new era where regenerative medicine takes center stage against genetic muscle wasting. The FDA has recently cleared an expansion for a Phase 2 clinical trial that evaluates the safety
Before undergoing advanced cell therapy, Martha Durden-Scroggins experienced extreme physical fluctuations, oscillating between periods of stability and bouts of debilitating weakness. At seventy-one, her aggressive B-cell lymphoma had reached a critical juncture where conventional interventions no
